Profile image
Senior Clinical Project Coord

Ms Barbara Yeung

HIV Epidemiology and Prevention Program
Phone
+61 (0)2 9385 0879
E-mail
byeung@kirby.unsw.edu.au
Dharan NJ; Jin F; Vaccher S; Bavinton B; Yeung B; Guy R; Carr A; Zablotska I; Amin J; Read P; Templeton DJ; Ooi C; Martin SJ; Ryder N; Smith DE; McNulty A; Brown K; Price K; Holden J; Grulich AE, 2023, 'Characteristics of Human Immunodeficiency Virus (HIV) Seroconversions in a Large Prospective Implementation Cohort Study of Oral HIV Preexposure Prophylaxis in Men Who Have Sex with Men (EPIC-NSW)', Clinical Infectious Diseases, 76, pp. E622 - E628, http://dx.doi.org/10.1093/cid/ciac660
2023
Amin J; Vaccher S; Templeton DJ; Bavinton B; Jin F; Zablotska I; Matthews G; Ogilvie E; Yeung B; Ooi C; Dharan N; Baker DA; Read P; Guy R; Grulich AE, 2022, 'Low Prior Exposure and Incidence of Hepatitis C in Human Immunodeficiency Virus–Negative Gay and Bisexual Men Taking Preexposure Prophylaxis (PrEP): Findings from the Expanded PrEP Implementation in Communities–New South Wales Prospective Implementation Study', Clinical Infectious Diseases, 75, pp. 1497 - 1502, http://dx.doi.org/10.1093/cid/ciac231
2022
Chan C; Fraser D; Vaccher S; Yeung B; Jin F; Amin J; Dharan NJ; Carr A; Ooi C; Vaughan M; Holden J; Power C; Grulich AE; Bavinton BR, 2021, 'Overcoming barriers to HIV pre-exposure prophylaxis (PrEP) coverage in Australia among Medicare-ineligible people at risk of HIV: Results from the MI-EPIC clinical trial', Sexual Health, 18, pp. 453 - 459, http://dx.doi.org/10.1071/SH21096
2021
Bavinton BR; Vaccher S; Jin F; Prestage GP; Holt M; Zablotska-Manos IB; Guy R; Amin J; Templeton DJ; Yeung B; Hammoud MA; Lewis D; Baker D; Dharan N; McNulty AM; Grulich AE, 2021, 'High Levels of Prevention-Effective Adherence to HIV PrEP: An Analysis of Substudy Data from the EPIC-NSW Trial', Journal of Acquired Immune Deficiency Syndromes, 87, pp. 1040 - 1047, http://dx.doi.org/10.1097/QAI.0000000000002691
2021
Jin F; Amin J; Guy R; Vaccher S; Selvey C; Zablotska I; Holden J; Price K; Yeung B; Ogilvie E; Quichua GC; Clackett S; McNulty A; Smith D; Templeton DJ; Bavinton B; Grulich AE, 2021, 'Adherence to daily HIV pre-exposure prophylaxis in a large-scale implementation study in New South Wales, Australia', AIDS, 35, pp. 1987 - 1996, http://dx.doi.org/10.1097/QAD.0000000000002970
2021
Grulich AE; Jin F; Bavinton BR; Yeung B; Hammoud MA; Amin J; Cabrera G; Clackett S; Ogilvie E; Vaccher S; Vickers T; McNulty A; Smith DJ; Dharan NJ; Selvey C; Power C; Price K; Zablotska I; Baker DA; Bloch M; Brown K; Carmody CJ; Carr A; Chanisheff D; Doong N; Finlayson R; Lewis DA; Lusk J; Martin S; Ooi C; Read P; Ryder N; Smith D; Tuck Meng Soo C; Templeton DJ; Vlahakis E; Guy R, 2021, 'Long-term protection from HIV infection with oral HIV pre-exposure prophylaxis in gay and bisexual men: findings from the expanded and extended EPIC-NSW prospective implementation study', The Lancet HIV, 8, pp. e486 - e494, http://dx.doi.org/10.1016/S2352-3018(21)00074-6
2021
Mcmanus H; Grulich AE; Amin J; Selvey C; Vickers T; Bavinton B; Zablotska I; Vaccher S; Jin F; Holden J; Price K; Yeung B; Cabrera Quichua G; Ogilvie E; Mcnulty A; Smith D; Guy R, 2020, 'Comparison of Trends in Rates of Sexually Transmitted Infections before vs after Initiation of HIV Preexposure Prophylaxis among Men Who Have Sex with Men', JAMA Network Open, 3, pp. e2030806, http://dx.doi.org/10.1001/jamanetworkopen.2020.30806
2020
Grulich AE; Guy R; Amin J; Jin F; Selvey C; Holden J; Schmidt HMA; Zablotska I; Price K; Whittaker B; Chant K; Cooper C; McGill S; Telfer B; Yeung B; Levitt G; Ogilvie EE; Dharan NJ; Hammoud MA; Vaccher S; Watchirs-Smith L; McNulty A; Smith DJ; Allen DM; Baker D; Bloch M; Bopage RI; Brown K; Carr A; Carmody CJ; Collins KL; Finlayson R; Foster R; Jackson EY; Lewis DA; Lusk J; O'Connor CC; Ryder N; Vlahakis E; Read P; Cooper DA; Smith D; Ooi C; Martin S; Soo TM; Templeton D; Townson D; Forssman B; Doong N; Han Thai G; Anderson B; MacLeod H; Parkhill N; Cooper D; Finlayson R; Law M, 2018, 'Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study', The Lancet HIV, 5, pp. e629 - e637, http://dx.doi.org/10.1016/S2352-3018(18)30215-7
2018
Martinello M; Hellard M; Shaw D; Petoumenos K; Applegate T; Grebely J; Yeung B; Maire L; Iser D; Lloyd A; Thompson A; Sasadeusz J; Haber P; Dore GJ; Matthews GV, 2016, 'Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II and DARE-C I studies', Antiviral therapy, 21, pp. 465, http://dx.doi.org/10.3851/IMP3073
2016
Martinello M; Hellard M; Shaw D; Petoumenos K; Applegate T; Grebely J; Yeung B; Maire L; Iser D; Lloyd A; Thompson A; Sasadeusz J; Haber P; Dore GJ; Matthews GV, 2016, 'Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II and DARE-C I studies', ANTIVIRAL THERAPY, 21, pp. 425 - 434, http://dx.doi.org/10.3851/IMP3035
2016
Alavi M; Spelman T; Matthews GV; Haber PS; Day C; van Beek I; Walsh N; Yeung B; Bruneau J; Petoumenos K; Dolan K; Kaldor JM; Dore GJ; Hellard M; Grebely J; Marks P; Amin J; Doab A; Carroll T; Teutsch S; Li H; Oon A; Cameron B; Lloyd A; White P; Rawlinson W; Jacqueline Flynn ; Goy K; Nguyen O; von Bibra S; Ffrench R; McCaughan G; Madden A; Farrell G; Crofts N; Sievert W; Baker D; Jacka B; Pan Y; Shaw D; Sasadeusz J; Crawford D; Phung N; George J; Bloch M; Hughes B; Mollison L; Roberts S; Desmond P; Acraman B, 2015, 'Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C', International Journal of Drug Policy, 26, pp. 976 - 983, http://dx.doi.org/10.1016/j.drugpo.2015.05.003
2015
Flynn JK; Dore GJ; Hellard M; Yeung B; Rawlinson WD; White PA; Kaldor JM; Lloyd AR; Ffrench RA; Dolan K, 2013, 'Maintenance of Th1 hepatitis C virus (HCV)-specific responses in individuals with acute HCV who achieve sustained virological clearance after treatment', Journal of Gastroenterology and Hepatology (Australia), 28, pp. 1770 - 1781, http://dx.doi.org/10.1111/jgh.12265
2013
Feld JJ; Grebely J; Matthews GV; Applegate T; Hellard M; Sherker A; Cherepanov V; Petoumenos K; Yeung B; Kaldor JM; Lloyd AR; Dore GJ, 2013, 'Plasma interferon-gamma-inducible protein-10 levels are associated with early, but not sustained virological response during treatment of acute or early chronic HCV infection', PLoS ONE, 8, pp. e80003, http://dx.doi.org/10.1371/journal.pone.0080003
2013
Grebely J; Feld JJ; Applegate T; Matthews GV; Hellard M; Sherker A; Petoumenos K; Zang G; Shaw I; Yeung B; George J; Teutsch S; Kaldor JM; Cherepanov V; Bruneau J; Shoukry NH; Lloyd AR; Dore GJ, 2013, 'Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection', Hepatology, 57, pp. 2124 - 2134, http://dx.doi.org/10.1002/hep.26263
2013
Flynn J; Dore GJ; Matthews G; Hellard M; Yeung B; Rawlinson W; White PA; Kaldor JM; Lloyd AR; Ffrench RA; Dolan K, 2012, 'Impaired hepatitis C virus (HCV)-specific interferon-responses in individuals with HIV who acquire HCV infection: Correlation with CD4 + T-cell counts', Journal of Infectious Diseases, 206, pp. 1568 - 1576, http://dx.doi.org/10.1093/infdis/jis544
2012
Grebely J; Hellard M; Applegate TL; Petoumenos K; Yeung B; Feld J; Rawlinson WD; Lloyd AR; George J; Kaldor JM; Dore GJ; Matthews G; Dolan K, 2012, 'Virological responses during treatment for recent hepatitis C virus: Potential benefit for ribavirin use in HCV/HIV co-infection', AIDS, 26, pp. 1653 - 1661, http://dx.doi.org/10.1097/QAD.0b013e3283553719
2012
Hellard M; Grebely J; Yeung B; Dore G; Marks P; Shaw D; Byrne M; Matthews G, 2012, 'EFFECTIVENESS OF RESPONSE-GUIDED THERAPY IN RECENT HEPATITIS C INFECTION: THE AUSTRALIAN TRIAL IN ACUTE HEPATITIS C', DRUG AND ALCOHOL REVIEW, 31, pp. 33 - 33
2012
Grebely J; Alavi M; Spelman T; Haber P; Day C; Matthews G; Van Beek I; Walsh N; Yeung B; Petoumenos K; Dolan K; Kaldor J; Dore G; Hellard M, 2012, 'IMPACT OF TREATMENT OF RECENTLY-ACQUIRED HEPATITIS C INFECTION ON INJECTING DRUG USE BEHAVIOURS', DRUG AND ALCOHOL REVIEW, 31, pp. 34 - 34
2012
Haber P; Hellard M; Matthews GV; Grebely J; Petoumenos K; Yeung B; Marks P; van Beek I; McCaughan G; White PA; Ffrench R; Rawlinson W; Lloyd A; Kaldor J; Dore GJ, 2009, 'Treatment of recent hepatitis C virus infection in a predominantly injection drug user cohort: the ATAHC Study', The Canadian Journal of Addiction, 1, pp. 33 - 33, http://dx.doi.org/10.1097/02024458-200912000-00072
2009
Haber P; Hellard M; Matthews GV; Grebely J; Petoumenos K; Yeung B; Marks P; Van Beek I; Kaldor J; Dore GJ, 2009, 'TREATMENT OF RECENT HEPATITIS C VIRUS INFECTION IN A PREDOMINANTLY INJECTION DRUG USER COHORT: THE ATAHC STUDY', DRUG AND ALCOHOL REVIEW, 28, pp. A27 - A27, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270916300083&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2009
Vaccher S; Amin J; Guy R; Jin F; Selvey C; Zablotska-Manos I; Holden J; Price K; Yeung B; Levitt G; Ogilvie E; McNulty A; Smith D; Cooper D; Grulich A, 2018, 'Baseline preferences for daily and non-daily PrEP dosing in EPIC-NSW', in Australasian HIV and AIDS Conference Handbook, Sydney, Australia, presented at Australasian HIV and AIDS Conference, Sydney, Australia, 26 September 2018, https://az659834.vo.msecnd.net/eventsairaueprod/production-ashm-public/36f06f6908734ab9a17095cab8705e35
2018
Martinello M; Petoumenos K; Grebely J; Gane E; Hellard M; Shaw D; Sasdeusz J; Applegate T; Lamoury F; Yeung B; Maire L; Dore G; Matthews G, 2016, 'INCIDENCE OF HCV REINFECTION AMONG TREATED INDIVIDUALS WITH RECENTLY ACQUIRED INFECTION', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, SPAIN, Barcelona, Vol. 64, pp. S620 - S621, presented at EASL International Liver Congress, SPAIN, Barcelona, 13 April 2016 - 17 April 2016, http://dx.doi.org/10.1016/S0168-8278(16)01152-1
2016
Martinello M; Hellard M; Shaw D; Petoumenos K; Applegate T; Grebely J; Yeung B; Maire L; Iser D; Lloyd A; Thompson A; Sasadeusz J; Haber P; Dore GJ; Matthews GV, 2014, 'Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: The ATAHC II and DARE-C i studies', in Antiviral Therapy, SAGE Publications, MA, Boston, pp. 425 - 434, presented at 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 07 November 2014 - 11 November 2014, http://dx.doi.org/10.3851/IMP3035
2014
Grebely J; Feld JJ; Applegate T; Matthews G; Hellard M; Sherker A; Petoumenos K; Shaw I; Yeung B; Kaldor JM; Cherepanov V; Bruneau J; Lloyd A; Shoukry N; Dore G, 2012, '889 PLASMA IP10 LEVEL PREDICTS SPONTANEOUS CLEARANCE IN ACUTE HCV INFECTION', in Journal of Hepatology, Elsevier, SPAIN, Barcelona, pp. s346, presented at 47th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), SPAIN, Barcelona, 18 April 2012 - 22 April 2012, http://dx.doi.org/10.1016/s0168-8278(12)60901-5
2012
Feld JJ; Grebely J; Applegate T; Matthews GV; Hellard M; Suppiah V; Sherker A; Petoumenos K; Shaw I; Yeung B; Rawlinson W; Booth D; Kaldor JM; Lloyd AR; Dore GJ, 2011, 'IP-10 IS ASSOCIATED WITH EARLY VIRAL KINETICS, BUT NOT SUSTAINED VIROLOGICAL RESPONSE DURING TREATMENT FOR RECENT HEPATITIS C VIRUS INFECTION', in JOURNAL OF HEPATOLOGY, ELSEVIER, GERMANY, Berlin, pp. S455 - S455, presented at 46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), GERMANY, Berlin, 30 March 2011 - 03 April 2011, http://dx.doi.org/10.1016/S0168-8278(11)61154-9
2011
Grebely J; Matthews GV; Hellard M; Suppiah V; Petoumenos K; Applegate T; Yeung B; Rawlinson W; Feld J; Lloyd AR; Booth D; Kaldor JM; George J; Dore GJ, 2011, 'IL28B GENOTYPE HAS VARIABLE INFLUENCE ON EARLY VIRAL KINETICS, BUT NO INFLUENCE ON SUSTAINED VIROLOGICAL RESPONSE DURING TREATMENT FOR RECENT HEPATITIS C VIRUS INFECTION', in JOURNAL OF HEPATOLOGY, ELSEVIER, GERMANY, Berlin, pp. S524 - S524, presented at 46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), GERMANY, Berlin, 30 March 2011 - 03 April 2011, http://dx.doi.org/10.1016/S0168-8278(11)61330-5
2011
Grebely J; Alavi M; Haber P; Day C; Matthews GV; van Beek I; Walsh N; Yeung B; Petoumenos K; Dolan K; Spelman T; Kaldor JM; Dore GJ; Hellard M, 2011, 'IMPACT OF TREATMENT ON INJECTING DRUG USE BEHAVIORS DURING RECENT HCV INFECTION: THE ATAHC STUDY', in JOURNAL OF HEPATOLOGY, ELSEVIER, GERMANY, Berlin, pp. S174 - S174, presented at 46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), GERMANY, Berlin, 30 March 2011 - 03 April 2011, http://dx.doi.org/10.1016/S0168-8278(11)60431-5
2011
Matthews GV; Alavi M; Grebely J; Petoumenos K; Yeung B; Hellard M; Lloyd A; van Beek I; Kaldor J; Haber P; Dore GJ, 2010, 'Depression prior to and during treatment for recent hepatitis C virus (HCV) infection among HCV and HCV/HIV participants in the ATAHC study', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, ENGLAND, London, pp. A21 - A21, presented at 12th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV, ENGLAND, London, 04 November 2010 - 06 November 2010, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000287431200041&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2010
Matthews GV; Alavi M; Grebely J; Petoumenos K; Yeung B; Hellard M; Lloyd A; van Beek I; Kaldor J; Haber P; Dore GJ, 2010, 'Depression prior to and during treatment for recent hepatitis C virus (HCV) infection among HCV and HCV/HIV participants in the ATAHC study', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, ENGLAND, London, pp. A21 - A21, presented at 12th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV, ENGLAND, London, 04 November 2010 - 06 November 2010, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000287431500027&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2010
Matthews GV; Grebely J; Hellard M; Yeung B; Marks P; Rawlinson W; Kaldor J; Dore GJ, 2010, 'WEEK 4 HCV RNA IS THE OPTIMAL PREDICTOR OF SVR IN BOTH HIV POSITIVE AND NEGATIVE SUBJECTS WITHIN THE AUSTRALIAN TRIAL IN ACUTE HCV', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, AUSTRIA, Vienna, pp. S116 - S116, presented at 45th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, AUSTRIA, Vienna, 14 April 2010 - 18 April 2010, http://dx.doi.org/10.1016/S0168-8278(10)60278-4
2010
Matthews GV; Grebely J; Hellard M; Yeung B; Marks P; Rawlinson W; Kaldor J; Dore G, 2010, 'DIFFERENCES IN EARLY VIROLOGICAL DECLINE IN INDIVIDUALS TREATED WITHIN THE AUSTRALIAN TRIAL IN ACUTE HCV SUGGEST A POTENTIAL BENEFIT FOR THE USE OF RIBAVIRIN', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Vienna, AUSTRIA, pp. S28 - S28, presented at 45th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Vienna, AUSTRIA, 14 April 2010 - 18 April 2010, http://www.journal-of-hepatology.eu/article/S0168-8278(10)60062-1/abstract
2010
Dore GJ; Hellard M; Matthews G; Grebely J; Haber PS; Petoumenos K; Yeung B; Marks P; van Beek I; McCaughan GW; White PA; Ffrench RA; Rawlinson W; Lloyd AR; Kaldor J, 2009, 'TREATMENT OF RECENT HEPATITIS C VIRUS INFECTION IN A PREDOMINANTLY INJECTION DRUG USER COHORT: THE ATAHC STUDY', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 723A - 723A, presented at 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 30 October 2009 - 03 November 2009, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270456000887&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2009
Hellard M; Dore G; Haber P; Marks P; Matthews G; Yeung B; Nguyen O; Pan Y; Ffrench R; McCaughan G; Van Beek I; White P; Dolan K; Rawlinson W; Lloyd A; Kaldor J, 2006, 'Australian trial in acute hepatitis C: preliminary findings', in JOURNAL OF CLINICAL VIROLOGY, ELSEVIER SCIENCE BV, FRANCE, Paris, pp. S139 - S139, presented at 12th International Symposium on Viral Hepatitis and Liver Disease, FRANCE, Paris, 01 July 2006 - 05 July 2006, http://dx.doi.org/10.1016/S1386-6532(06)80430-0
2006
Hellard M; Haber P; Day C; Marks P; Matthews G; Yeung B; Nguyen O; Dolan K; Van Beek I; Kaldor J; Dore G, 2006, 'Australian trial in acute hepatitis C: baseline behavioural data', in JOURNAL OF CLINICAL VIROLOGY, ELSEVIER SCIENCE BV, FRANCE, Paris, pp. S140 - S140, presented at 12th International Symposium on Viral Hepatitis and Liver Disease, FRANCE, Paris, 01 July 2006 - 05 July 2006, http://dx.doi.org/10.1016/S1386-6532(06)80434-8
2006